Novo Nordisk (NYSE:NVO) shares have moved slightly higher today, catching the eye of investors who track the pharmaceutical sector. The stock is up around 2% in recent trading, prompting some interest ...

It appears problems at Novo Nordisk’s recently acquired manufacturing facility in Indiana aren’t going to be solved any time soon. The FDA has tagged the former Catalent facility with an official ...

Novo Nordisk lobbies to maintain Medicaid coverage for Wegovy Some states face financial strain from Wegovy's cost and demand Novo says obesity is a treatable disease, patients deserve access to care ...

Novo Nordisk NOVO.B2.49%increase; green up pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...

Oct 22 (Reuters) - Shares of Novo Nordisk (NOVOb.CO), opens new tab fell around 3% on Wednesday, extending their losses from a day earlier, after the Wegovy maker's top investor proposed a sweeping ...

The Food and Drug Administration approved Novo Nordisk’s NOVO.B1.23%increase; green up pointing triangle oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults ...

Pressured by its top shareholder, Novo Nordisk on Tuesday said key board members will be replaced. Pressured by its key shareholder, the Novo Nordisk Foundation, the company said its chairman, Helge ...

Bagsværd, Denmark, 21 October 2025 - Novo Nordisk today announced that the Board of Directors have decided to convene an Extraordinary General Meeting to elect new members of the Board of Directors of ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. A troubled Indiana ...

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks of the year ...

Initiating coverage on Novo Nordisk with a Strong Buy, 70% below its all-time high. NVO's competitive pressures and US political pricing risks are midterm noise. Global obesity and diabetes markets ...

After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular events (MACE), the FDA has followed suit with a MACE expansion for its ...